Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Beigene ADS Representing Ord Shs BGNE

Healthcare Biotechnology
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.


NDAQ:BGNE - Post by User

Beigene ADS Representing Ord Shs
<< Previous
 Bullboard Posts
User Avatar Image
(229)
•••
Post by whytestockson Sep 30, 2024 3:17pm
554 Views
Post# 36247220

BeiGene Ltd. (NASDAQ: BGNE) Records 52-Week High Monday Morn

BeiGene Ltd. (NASDAQ: BGNE) Records 52-Week High Monday Morn
JUST IN: $BGNE BeiGene Ltd. (NASDAQ: BGNE) Records 52-Week High Monday MorningShares of BeiGene, Ltd. (NASDAQ: BGNE) traded at a new 52-week high today and are currently trading at $230.59. So far today, approximately 142.34k shares have been exchanged, as compared to an average 30-day volume of 272.72k shares. BeiGene, Ltd., a biotechnology company, focuses on discove...BGNE - BeiGene Ltd. (NASDAQ: BGNE) Records 52-Week High Monday Morning

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities